Microsalt PLC — Proxy Solicitation & Information Statement 2026

Jun 5, 2026

National Storage Mechanism | Additional information

RNS Number : 1055H

MicroSalt PLC

05 June 2026

5 June 2026

MicroSalt Plc

("MicroSalt" or the "Company")

Notice of AGM

MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt with approximately 50% less sodium, announces that it will be holding its Annual General Meeting, at the offices of Bird & Bird LLP, 12 New Fetter Lane, London EC4A 1JP on 30 June 2026 at 11.00 a.m. (BST). The annual report and the formal notice of the 2026 AGM will today be posted to shareholders.

The notice of AGM is available to review on the Company's website at: https://microsaltinc.com/

For more information, please visit https://microsaltinc.com, follow on X @MicroSaltPLC or contact:

MicroSalt plc	Via Gracechurch Group
Rick Guiney, CEO
Zeus (Nominated adviser and broker) David Foreman / James Edis (Investment Banking)	+44 (0)20 3829 5000
Gracechurch Group (Financial PR)	+44 (0)20 4582 3500
Heather Armstrong, Alexis Gore, Rebecca Scott

About MicroSalt

MicroSalt is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges. Year to date through 2025, MicroSalt has contributed to more than 634M servings made healthier.

Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year. 

Operational since 2018, MicroSalt has established a defensible IP portfolio, holding a granted US patent and 14 pending applications worldwide. These protections create significant barriers to entry in a market expected to grow exponentially as regulation and consumer demand accelerate.

MicroSalt is ideally positioned for scale and market leadership, with clear pathways into food manufacturing, consumer channels, and ultimately the broader £10+ billion global salt market. MicroSalt is more than a healthier alternative-it is a disruptive, category-defining solution poised to deliver significant commercial and societal impact.

For more information, please visit www.microsaltinc.co or follow on X @microSaltPLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAFZGGVRDRGVZM